AZ fills top R&D spot with Genentech's Bohen; Regulators OK Pfizer's Hospira deal;

> Genentech's Sean Bohen will take up the post as AstraZeneca's ($AZN) R&D chief. More

> Regulators have approved Pfizer's ($PFE) Hospira ($HSP) buyout deal, pending the divestiture of some sterile injectable drugs. Report

> Bayer HealthCare has launched a digital healthcare accelerator in Berlin. Report

> South Korean pharmaceutical companies are beefing up their presence in the global healthcare industry through global partnerships. More

> Merck KGaA will close down Bangalore GeNei, a company it acquired in 2009 to boost its capabilities in design, development and production of biological research products. More

And Finally... Google's ($GOOG) Life Sciences division is developing a wearable blood glucose monitor that could revolutionize diabetic care and treatment. Report

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.

Weeks after launching a U.S. trial to evaluate IL-6 inhibitor Kevzara for COVID-19, Sanofi and Regeneron have launched a matching study abroad.